Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data.

Hopkins, Ashley M; Shahnam, Adel; Zhang, Sasha; Karapetis, Chris S; Rowland, Andrew; Sorich, Michael J

Hopkins, Ashley M; Shahnam, Adel; Zhang, Sasha; Karapetis, Chris S; Rowland, Andrew; Sorich, Michael J.

Afiliación

Hopkins AM; Flinders Centre for Innovation in Cancer, Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia.
Shahnam A; The Canberra Hospital, Garran 2605, Australia.
Zhang S; Flinders Centre for Innovation in Cancer, Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia.
Karapetis CS; Flinders Centre for Innovation in Cancer, Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia.
Rowland A; Flinders Centre for Innovation in Cancer, Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia.
Sorich MJ; Flinders Centre for Innovation in Cancer, Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia.

Cancer Biol Med ; 16(2): 341-349, 2019 May.

Article en En | MEDLINE | ID: mdl-31516754

Palabras clave

Afatinib; non-small cell lung cancer; prognostic model

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Biol Med Año: 2019 Tipo del documento: Article País de afiliación: Australia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google